Afamelanotide
Also known as: [Nle4,D-Phe7]-α-MSH, Afamelanotide, AP-001, BMS‑192,131, CUV1647, MT-II precursor analog, NDP-MSH, Scenesse
Source Afamelanotide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Afamelanotide is a synthetic analogue of α‑melanocyte‑stimulating hormone that activates melanocortin‑1 receptors to boost melanin production. It is approved as a prescription drug and administered subcutaneously, primarily to lessen painful photosensitivity in X‑linked protoporphyria. Emerging literature also discusses its experimental use for vitiligo repigmentation and acne, but clinical data outside protoporphyria remain limited.
Mechanism of Action
Afamelanotide binds to melanocortin‑1 receptors (MC1R) on melanocytes, mimicking the natural α‑MSH peptide. Receptor activation triggers the cyclic AMP pathway, up‑regulating tyrosinase and other enzymes that drive eumelanin synthesis. The resulting increase in melanin provides a photoprotective shield that absorbs ultraviolet radiation, reduces oxidative stress, and may modulate inflammatory pathways in skin disorders.
What the Research Shows
The GeneReviews entry on X‑linked protoporphyria cites afamelanotide as a therapeutic that reduces phototoxic pain, indicating its clinical use in this rare disorder. Two recent reviews of vitiligo list afamelanotide among emerging treatments, noting its ability to stimulate pigmentation, but they emphasize the need for longer‑term efficacy and safety data. An acne review mentions afamelanotide as a promising candidate that could attenuate Akt/mTORC1 signaling, yet no clinical trials are referenced. Overall, the literature provides solid evidence for photoprotection in protoporphyria, while data for vitiligo and acne are primarily pre‑clinical or anecdotal.
Reported Benefits
In X‑linked protoporphyria, afamelanotide has been reported to lessen the intensity and duration of phototoxic reactions, improving patients' tolerance to sunlight. By increasing melanin, it may aid repigmentation in vitiligo and theoretically reduce inflammatory signaling in acne, offering a novel, non‑steroidal approach to these conditions. Its subcutaneous delivery allows sustained drug levels over weeks.
Limitations of the Evidence
Evidence outside protoporphyria is limited to narrative reviews; no randomized controlled trials for vitiligo or acne have been published in the cited abstracts. The long‑term durability of repigmentation or acne improvement remains unknown. Additionally, the drug is approved only for protoporphyria, so off‑label use lacks regulatory endorsement and robust safety data.
Safety Considerations
Afamelanotide is generally well tolerated, with the most common adverse events being mild hyperpigmentation, nausea, headache, and occasional injection‑site reactions. Because it increases melanin, there is a theoretical risk of excessive pigmentation in sun‑exposed areas. Patients with a history of melanoma or other pigment‑related disorders should be monitored, and the drug is contraindicated in individuals with hypersensitivity to the peptide.
How It Is Administered
The drug is supplied as a biodegradable subcutaneous implant that releases afamelanotide over several weeks (typically 16‑day duration). It is inserted by a healthcare professional under sterile conditions. No oral or topical formulations are currently approved.
Routes of Administration
Goals & Uses
- Vitiligo repigmentationInvestigational UseLow
- Reduction of phototoxic pain episodesSymptom ManagementHigh
- Prevention of phototoxic reactions in erythropoietic protoporphyriaDisease ManagementHigh
- Erythropoietic protoporphyria (EPP)TherapeuticHigh
- Xeroderma pigmentosum (XP) – investigationalTherapeuticModerate
- Solar urticaria managementInvestigational UseLow
- Variegate porphyria photoprotectionInvestigational UseLow
- Increased skin melanin/pigmentationPhotoprotectionHigh
- Photoprotection for other photosensitivity disordersResearchModerate
- Erythropoietic protoporphyria (photosensitivity)IndicationHigh
Contraindications
- Other active malignant melanocytic lesionsOncologicHigh
- Melanoma or history of melanomaOncologicHigh
- PregnancyPopulationModeratePotential fetal risk or insufficient safety data
- Hypersensitivity to afamelanotide or excipientsAllergy/immunologicHigh
- Renal or hepatic impairment (severe)Organ ImpairmentModerate
- BreastfeedingPopulationModeratePotential transfer into breast milk or insufficient safety data
- Active malignant melanomaOncologyHigh
- Active malignant melanoma or other pigmented skin cancersOncologyHigh
- Known hypersensitivity to afamelanotide or any excipientsAllergyHigh
Adverse Effects
- HeadacheNeurologicCommonPain in the head or upper neck
- Hyperpigmentation of skin and mucous membranesDermatologicCommon
- HypotensionCardiovascularUncommonLow blood pressure
- Hyperpigmentation of skinDermatologicCommon
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- Implant site reactions (bruising, pain, scarring)Local/dermatologicCommon
- FatigueGeneralUncommonLow energy or tiredness
- Injection site reactionLocalCommonRedness, swelling, itching, bruising, or pain at the injection site
- HyperpigmentationDermatologicCommon
- Injection‑site pain or erythemaLocalCommon
- New or changed melanocytic neviDermatologicUncommon
Drug Interactions
- Immunosuppressants (e.g., cyclosporine)Low
- Photosensitizing agents (e.g., tetracyclines)Moderate
- Photosensitizing agentsModerate
- ImmunosuppressantsLowPotential interaction with immune pathways or infection risk
Population Constraints
- PregnancyReproductive SafetyRelative
- Pediatric patients (<18 years)AgeRelative
- Breastfeeding womenReproductiveRelative
- Patients <12 yearsAgeAbsolute
- Patients with severe hepatic impairmentHepaticRelative
- Patients with numerous atypical neviDermatologic RiskRelative
- Pregnant womenReproductiveRelative
- Children <12 yearsAgeRelative
- Patients with personal or family history of melanomaOncologic HistoryAbsolute
Regulatory Status
- European UnionApprovedApproved: erythropoietic protoporphyriaAuthorized in multiple EU member states.
- United StatesApprovedApproved: erythropoietic protoporphyriaMarketed as Scenesse; subcutaneous implant.
- United KingdomApprovedApproved: erythropoietic protoporphyriaAvailable via prescription.
Approved in the US (Scenesse) and EU for erythropoietic protoporphyria; administered via subcutaneous implant; not indicated for cosmetic tanning.
Evidence & Sources
- Journal ArticleModerateDiotallevi F, et al.2023-01-01T00:00:00.000000Z
- Journal ArticleModerateAdam MP, et al.1993-01-01T00:00:00.000000Z
- Journal ArticleModerateCong TX, et al.2019-01-01T00:00:00.000000Z
- Journal ArticleModerateIsmail IB, Bhat YJ, Ul Islam MS2025-01-01T00:00:00.000000Z
- Journal ArticleModeratePerez-Bootello J, et al.2023-01-01T00:00:00.000000Z
Frequently Asked Questions
What condition is afamelanotide officially approved to treat?
Afamelanotide is approved as a prescription medication for reducing painful photosensitivity in patients with X‑linked protoporphyria, a rare disorder that causes severe skin reactions to sunlight.
Can afamelanotide be used for vitiligo or acne?
While reviews suggest potential benefits for vitiligo repigmentation and acne inflammation, there are no published clinical trials confirming efficacy. Use for these conditions remains experimental and off‑label.
How is the drug administered and how long does it act?
It is delivered as a subcutaneous implant that slowly releases the peptide over about two weeks, providing continuous melanocortin receptor activation without daily dosing.
What side effects should patients be aware of?
Common side effects include mild hyperpigmentation, nausea, headache, and occasional injection‑site irritation. Excessive darkening of the skin can occur, and patients with a history of melanoma should be evaluated carefully.
Is afamelanotide safe for long‑term use?
Long‑term safety data are robust for protoporphyria, but limited for other skin conditions. Ongoing monitoring for pigmentation changes and any unexpected reactions is recommended during extended therapy.
What is Afamelanotide?
Afamelanotide is a synthetic analogue of α‑melanocyte‑stimulating hormone that activates melanocortin‑1 receptors to boost melanin production. It is approved as a prescription drug and administered subcutaneously, primarily to lessen painful photosensitivity in X‑linked protoporphyria. Emerging literature also discusses its experimental use for vitiligo repigmentation and acne, but clinical data outside protoporphyria remain limited.
What is Afamelanotide used for?
Afamelanotide is educationally associated with: Vitiligo repigmentation, Reduction of phototoxic pain episodes, Prevention of phototoxic reactions in erythropoietic protoporphyria, Erythropoietic protoporphyria (EPP), Xeroderma pigmentosum (XP) – investigational, Solar urticaria management, Variegate porphyria photoprotection, Increased skin melanin/pigmentation, Photoprotection for other photosensitivity disorders, Erythropoietic protoporphyria (photosensitivity). Educational only — not medical advice.
How is Afamelanotide administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of Afamelanotide?
Reported adverse effects include: Headache, Hyperpigmentation of skin and mucous membranes, Hypotension, Hyperpigmentation of skin, Nausea, Implant site reactions (bruising, pain, scarring), Fatigue, Injection site reaction, Hyperpigmentation, Injection‑site pain or erythema, New or changed melanocytic nevi. This list is not exhaustive — consult a qualified clinician.
Who should avoid Afamelanotide?
Recorded contraindications: Other active malignant melanocytic lesions, Melanoma or history of melanoma, Pregnancy, Hypersensitivity to afamelanotide or excipients, Renal or hepatic impairment (severe), Breastfeeding, Active malignant melanoma, Active malignant melanoma or other pigmented skin cancers, Known hypersensitivity to afamelanotide or any excipients. Consult a qualified clinician before use.